In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

5 days ago

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

Last week

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

3 weeks ago

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse pop­u­la­tions

4 weeks ago

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

Last month

Obe­si­ty drug de­vel­op­ment—still room to grow

2 months ago

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

2 months ago

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

2 months ago

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

2 months ago

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

2 months ago

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

3 months ago

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

3 months ago

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

5 months ago

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

5 months ago

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

6 months ago

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

6 months ago

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

6 months ago

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

6 months ago

Bio­phar­ma and medtech mar­kets ad­vance to­ward equi­lib­ri­um: 2024 life sci­ences clus­ter analy­sis

7 months ago

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

7 months ago

CMIC: Japan’s lead­ing CRO fo­cus­es on the fu­ture of clin­i­cal tri­als with in­no­va­tion and dig­i­tal so­lu­tions

7 months ago

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

7 months ago

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

7 months ago

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just that

8 months ago
1234 Next page Last page
A service from the Financial Times